Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART

Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA)*

(2010)   TROPICAL MEDICINE & INTERNATIONAL HEALTH

Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial

(2009)   LANCET

High Sensitivity of Human Leukocyte Antigen–B*5701 as a Marker for Immunologically Confirmed Abacavir Hypersensitivity in White and Black Patients

(2008) Michael Saag et al.   CLINICAL INFECTIOUS DISEASES

Should HLA‐B*5701 Screening Be Performed in Every Ethnic Group before Starting Abacavir?

(2008) Wan Beom Park et al.   CLINICAL INFECTIOUS DISEASES

HLA-B*5701 Screening for Hypersensitivity to Abacavir

(2008) Simon Mallal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility

(2008) A R Hughes et al.   PHARMACOGENOMICS JOURNAL

CNA110329: a prospective epidemiological study to determine the prevalence of HLA-B*5701 in HIV-1 infected individuals in five European countries

(2008) JM Prins et al.   Journal of the International AIDS Society